Evolving Practices: Navigating Patient Care in Newly Diagnosed & R/R Multiple Myeloma

EP. 1: Preferred Induction Regimen for Transplant-Eligible Patients with Newly-diagnosed Multiple Myeloma

September 30th 2025

EP. 2: Guideline Recommendations for Risk Stratification

September 30th 2025

EP. 3: Selecting Between Quadruplet Induction Regimens

October 7th 2025

Panelists discuss how data from the Perseus and Ischaemia trials inform their selection of quadruplet induction regimens and use of MRD negativity as a treatment endpoint before transplant.

EP. 4: Managing Adverse Events for Patients Receiving Quadruplet Induction Regimens

October 7th 2025

Panelists discuss how they manage adverse events in patients receiving quadruplet induction, particularly focusing on neuropathy prevention, dexamethasone dose reduction, infection prophylaxis, and IgG monitoring strategies.

EP. 5: Selecting the Proper Maintenance Therapy

October 14th 2025

Panelists discuss how they approach maintenance therapy after transplant, tailoring treatment intensity based on risk stratification and considering clinical trials versus standard lenalidomide or doublet regimens.

EP. 6: Exploring Minimal Residual Disease in Multiple Myeloma

October 14th 2025

Panelists discuss how they utilize minimal residual disease testing at various timepoints post-transplant to guide maintenance decisions and assess the potential for treatment discontinuation in sustained MRD-negative patients.

EP. 7: Frontline Induction Therapy for Transplant-Ineligible or Transplant-Deferred Patients

October 21st 2025

Panelists discuss how they approach frontline therapy for transplant-ineligible or deferred patients, emphasizing reduced-intensity quadruplets for frail patients while considering transplant eligibility more broadly for fit older adults.

EP. 8: Bispecific Antibody Therapies for Relapsed or Refractory Multiple Myeloma

October 21st 2025

Panelists discuss how they sequence bispecific antibodies with CAR-T therapy in relapsed/refractory multiple myeloma, preferring CAR-T before BCMa bispecifics and considering GPR-C5 targeting as bridging therapy.

EP. 9: Step-up Dosing with Bispecifics

October 28th 2025

Panelists discuss how they implement step-up dosing for bispecific antibodies, transitioning from inpatient to outpatient approaches using prophylactic tocilizumab and existing infrastructure from CAR-T and transplant programs.

EP. 10: Aligning Real-world and Clinical Trial Data

October 28th 2025

Panelists discuss how real-world outcomes with bispecific antibodies align closely with clinical trial data in terms of response rates, though with lower infection rates due to improved prophylaxis strategies.